NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Alterity Therapeutics Limited ATHE
10 fiscal years on record · AUD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
AUD -0.19
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 10-year series below
Revenue
Net income
Per share
AUD -0.19
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-37.2%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
AUD 46.0M
total assets, end of FY2024
Total assetsAUD 46.0M
EquityAUD -225.9M
CashAUD 33.2M
Current ratio12.98×
Equity funds -491% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · AUD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue AUD B
·
·
·
·
·
·
·
0.0
0.0
0.0
Operating income AUD B
·
·
·
·
·
·
·
·
·
·
EBITDA AUD B
·
·
·
·
·
·
·
·
·
·
Income tax AUD B
0.0
0.0
0.0
0.0
·
·
0.0
0.0
0.0
0.0
Net income AUD B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted AUD
−0.19
−0.52
−0.57
−0.53
−0.90
−1.50
−2.00
·
·
·
Dividend / sh AUD
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
2.44
2.41
2.08
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 6 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed